Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

One new study found that heart attack survivors benefited from a medicine long used to treat gout. Several experimental drugs also showed early promise for interfering with heart-harmful genes without modifying the genes themselves in one case, with treatment just twice a year. The research was featured at an American Heart Association conference ending Monday in Philadelphia. "There's a lot of excitement" about the new gene-targeting medicines, especially because they seem to last so long, said Dr. Karol Watson, of the University of California, Los Angeles. Scientists have been exploring gene therapy altering DNA to attack the root cause of many diseases. The new drugs essentially accomplish the same thing without tampering with genes, said the University of Pennsylvania's Dr. Daniel Rader, who has consulted for some makers of these drugs. The medicines work by silencing or blocking messages that genes give to cells to make proteins that can do harm, such as allowing cholesterol to accumulate. The first few of these "RNA-interference" drugs recently were approved for other conditions, and research is also targeting heart disease. Farthest along is inclisiran, tested in 1,561 people with heart disease from clogged arteries who still had high LDL, the bad form of cholesterol, despite taking standard drugs. They were given a shot of inclisiran or a dummy drug when they joined the study, three months later and then every six months. The drug lowered LDL by 56% without serious side effects. More testing will show whether it also lowers heart attacks and other problems, not just cholesterol. Inclisiran's maker, The Medicines Company, plans to seek federal approval for it later this year. Two other RNA interference drugs aim at a different target triglycerides, another fat in the blood that's elevated in one quarter of Americans. Treatments include very low-fat diets, weight loss, fish oil and drugs, but doctors say more and better therapies are needed. Each RNA interference drug was tested at various doses in 40 people. A single shot lowered triglycerides by 30% to 67%, and the benefit lasted for at least four months. The studies were just intended to show safety; Arrowhead Pharmaceuticals is developing both drugs. Other research found new benefits from older drugs. AstraZeneca's Farxiga, originally developed to treat diabetes, also lowered the risk of heart problems in heart failure patients who did not have diabetes. Among 2,605 of such patients treated for 18 months, about 9% of those on Farxiga had worsening heart failure or heart-related death versus nearly 13% of those not given the drug. That worked out to a 27% lower risk, without extra serious side effects. Surprising benefits also were seen in a Canadian study of the decades-old gout drug. The anti-inflammatory drug colchicine sold as Colcrys, Mitigare and in generic form was tested in 4,745 people who recently had a heart attack. After about two years, colchicine users had a 23% lower risk of suffering a new heart attack, heart-related death, stroke, cardiac arrest or urgent need for an artery-opening procedure compared with a group given dummy pills. The benefit came mostly from preventing strokes and artery-opening procedures, and some heart doctors would rather have seen more difference in heart attacks and deaths. Colchicine is being tested in several other studies, and more evidence is needed before using it routinely to lower heart risks, Dr. L. Kristin Newby of Duke University wrote in a commentary published with the study in the New England Journal of Medicine. Dr. Donald Lloyd-Jones, a Northwestern University cardiologist and program chief for the heart conference, was more supportive. "When you have a safe drug that's easily available, it's going to be hard to hold this one back," he said. ___ Marilynn Marchione can be followed on Twitter at http://twitter.com/MMarchioneAP ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.
New, old drugs may offer fresh ways to fight heart disease.

"The story provides the cost of the CT scan as well as angiography. However, the story should have discussed insurance coverage for the scans. The story describes the percentage of patients with blockages that were identified with either the CT scan or the angiogram. The story should have also described the probability of having blockages with a positive scan (positive predictive value). This is the more important piece of information to a consumer. Also not described in the story is whether the CT scans had any impact at all on downstream outcomes, such as heart attacks, deaths, or procedures. The story correctly describes radiation exposure as one of the harms of the heart CT. The story could have described other harms, such as theimplications offalse positive or false negativetest results. The story adequately describes the design of the current study, including a criticism from one expert that the study ""cherry-picked"" patients to include in the study in order to maximize the findings. The story does not exaggerate the seriousness or prevalence of heart disease. However, the story could have been more clear about who the CT scans are intended for. The study in question was in those with suspected heart disease, not the assymptomatic or ""worried well"". The use of CT scans in the larger asymptomatic population is controversial. The story quotes multiple independent experts who provide valuable commentary on the implications of the new findings. The story mentions angiography as the alternative to the heart CT. The story clearly states that the CT scans are relatively new and available in many hospitals, however it is not clear how many hospitals have purchased these machines. The story adequately describes the novelty of the scans. Because the story quotes multiple experts, the reader can assume that the story did not rely on a press release as the sole source of information."
'Super X-rays' show promise for finding heart disease but produce high radiation dose

Branagh and Friel were among 11 winning performers and programs spanning eight countries: Belgium, Canada, France, Germany, Norway, Turkey, the United Kingdom and the United States. The awards are presented annually by the International Academy of Television Arts & Sciences, which represents more than 60 countries and 500 companies from all sectors of TV, including internet and mobile technology. The evening was hosted by Iranian-American comedian-actor Maz Jobrani, who co-stars on the CBS sitcom "Superior Donuts." "The International Emmys are like the World Cup of TV," Jobrani cracked, "and like the World Cup a lot of Americans don't know it's happening. Presenters included Kevin McKidd ("Grey's Anatomy"), talk-show veteran Larry King, Freddy Rodriguez ("Bull") and Melissa Villasenor ("Saturday Night Live"). Branagh won for his role as Swedish detective Kurt Wallander in the popular BBC drama series "Wallander," which has won an American following on public television's "Masterpiece." Friel was awarded for her performance as Sergeant Marcella Backland in the British series "Marcella" (which is available on Netflix). The other winners include: Arts: "Hip-Hop Evolution" (Canada). Comedy: "Alan Partridge's Scissored Isle" (United Kingdom). Documentary: "EXODUS: Our Journey to Europe" (United Kingdom). Drama Series: "Mammon II" (Norway). Non-English Language U.S. Primetime Program: "Sr. Avila" (carried on HBO Latin America). Non-Scripted Entertainment: "Sorry Voor Alles" ("Sorry About That"), (Belgium). Short-Form Series: "The Braun Family" (Germany). Telenovela: "Kara Sevda" ("Endless Love"), (Turkey). TV Movie or Miniseries: "Don't Leave Me" (France). In addition, the Emmy Directorate Award was presented to Emilio Azcarraga Jean, head of Grupo Televisa, the world's largest Spanish-language content provider as well as Mexico's largest broadcaster and pay-TV provider. Not present was Kevin Spacey, who had been announced as the 2017 recipient of the International Emmy Founders Award. His award was rescinded last month after allegations of past sexual misconduct became public. "The Academy felt that, in light of recent events, we could not present the award to him," Academy CEO Bruce L. Paisner told the room in his opening remarks. ___ Online: https://www.iemmys.tv
Branagh, Friel among winners of International Emmy Awards.